Ribometrix develops small molecule drugs that target RNA biology to prevent the production of disease-causing proteins, addressing challenges in treating complex diseases such as cancer and autoimmune disorders. By binding directly to mRNAs or mRNA-binding proteins, Ribometrix's platform offers a novel approach to drug discovery that aims to manipulate key regulatory mechanisms in human health.
Funding
$7.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DDFounders
Product
Problem
Many disease-causing proteins are produced through RNA, but traditional drug discovery largely targets proteins, leaving a significant portion of the proteome undruggable. This limitation hinders the development of effective treatments for complex diseases, including cancers and autoimmune disorders.
Solution
Ribometrix is pioneering a novel approach to drug discovery by developing small molecule therapeutics that directly target RNA biology. Their platform focuses on preventing the production of disease-driving proteins by binding directly to mRNAs or mRNA-binding proteins. This method allows for manipulation of key regulatory mechanisms, offering a unique opportunity to tackle difficult-to-drug targets and address a wide range of diseases. By combining innovative RNA technologies with traditional drug discovery approaches, Ribometrix aims to create oral drugs for autoimmune diseases and the opportunity to drug intracellular targets inaccessible to biologics.
Target Audience
The primary target audience includes patients suffering from cell proliferation disorders, central nervous system disorders, and autoimmune disorders, as well as pharmaceutical companies seeking novel drug discovery platforms.
Features
- Small molecule drugs that bind directly to mRNAs or mRNA-binding proteins
- Technology to prevent the production of disease-causing proteins
- Platform to manipulate key regulatory mechanisms in human health
- Focus on difficult-to-drug oncogenes, CNS disorders, and autoimmune disorders
- Oral drugs for autoimmune diseases and intracellular targets inaccessible to biologics